Re: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

J Natl Cancer Inst. 2005 Apr 6;97(7):542; author reply 542-3. doi: 10.1093/jnci/dji090.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / prevention & control*
  • Confounding Factors, Epidemiologic
  • Cyclooxygenase 2
  • Double-Blind Method
  • Drug Synergism
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Humans
  • Incidence
  • Membrane Proteins
  • Osteoporosis, Postmenopausal / complications*
  • Prostaglandin-Endoperoxide Synthases / drug effects*
  • Raloxifene Hydrochloride / administration & dosage
  • Raloxifene Hydrochloride / adverse effects*
  • Randomized Controlled Trials as Topic
  • Selective Estrogen Receptor Modulators / administration & dosage
  • Selective Estrogen Receptor Modulators / adverse effects*
  • Thromboembolism / chemically induced*
  • Treatment Outcome
  • United States / epidemiology

Substances

  • Enzyme Inhibitors
  • Membrane Proteins
  • Selective Estrogen Receptor Modulators
  • Raloxifene Hydrochloride
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases